

Document title: EF CLIF Publication Policy	Document code/version no.: EFCLIF-POL-09 v02
Status:	Life

Purpose

This document sets out the policy of EF CLIF as regards authorship of publications and acknowledgement. EF CLIF encourages researchers who use samples and/or data generated from studies promoted and/or funded by EF CLIF to provide open access to publications and any other research output.

Scope and application

The mandates of this policy apply to all researchers that participate in research activities using data and/or samples collected, processed, analyzed, stored and managed by EF CLIF.

This document is to be used in conjunction with other applicable policies or legally binding contracts (i.e., material transfer agreements, data transfer agreements, collaboration or partnership agreements).

This document applies to a variety of publication types including, but not limited to, peer-reviewed scientific research articles, pre-prints, conference abstracts and presentations.

For updates, please refer to the latest [EF CLIF Publication Policy](#) on the EF CLIF website.

Acknowledgement

For scientific research articles, the following funding acknowledgement statement should be used:

This research was made possible through access to data and/or samples generated by the [acronym] study, promoted and funded by the European Foundation for the Study of Chronic Liver Failure (EF CLIF), a private, non-profit research organization supported by unrestricted grants from Grifols and Genfit.

For abstracts, and oral or poster presentations, a shorter version of the above funding acknowledgement statement should be used:

This research was made possible through access to data and/or samples generated by the [acronym] study, promoted and funded by the European Foundation for the Study of Chronic Liver Failure (EF CLIF).

Researchers are encouraged to display the project logo on their oral and poster presentations together with the EF CLIF special logo for sponsored studies.

Authorship

All authors of each publication related to EF CLIF-promoted and -funded projects will be identified in accordance with the recommendations issued by the [International Committee of Medical Journal Editors \(ICMJE\)](#).

All scientific information (i.e., peer-reviewed scientific research articles, data and samples underlying publications) resulting from EF CLIF-promoted and funded studies must adhere to the specific requirements of the study protocol that generated the data and samples. Study protocols, as well as exploratory results and preliminary findings presented at internal meetings are privileged and confidential communications. Any participating researcher, including Regional Coordinators and members of the Study Core Group, wanting to present any project-related information at a conference must register their interest to the EF CLIF General Manager via email at efclif@efclif.com.

For studies promoted and funded by EF CLIF, no individual participating researcher can perform analyses or interpretations or seek publication of any research data collected in their own center unless approved by the appointed Study Core Group.

- For EF CLIF-promoted and -funded studies, the decision as to who will be credited as an author of a publication and the author sequence is established in each study protocol. The primary foundation papers will include the Principal Investigator(s) as (co-)first author(s).
- For each EF CLIF-promoted and -funded study, the participants who contributed with sample collection should be included as authors to reflect their contribution.
- Individual EF CLIF staff members who have made a relevant contribution to the paper to warrant authorship should be given credit as an author.
- For publications derived from approved ancillary studies, the Principal Investigator(s) of the parent EF CLIF study will be listed as senior author(s). The full list of researchers who participated in the parent study will be included

in the author line or as supplementary materials whenever appropriate.

- For publications related to research activities within the EASL Chair, the following statement should be added to the authors list: “A study of the EASL-CLIF Consortium, a research network of EF CLIF”.
- For publications related to research activities within the Grifols Chair, the following statement should be added to the author’s list: “A study of the Grifols Chair – European Network for Translational Research-Chronic Liver Failure (ENTR-CLIF), a research network of EF CLIF”.
- For publications related to research activities within the EASL Chair and the Grifols Chair, the following statement should be added to the author’s list: “A study of the EASL- CLIF Consortium and the Grifols Chair – European Network for Translational Research-Chronic Liver Failure (ENTR-CLIF), two research networks of EF CLIF”.

Review of publications and abstracts by EF CLIF

All manuscripts and abstracts need to be sent out to EF CLIF via email at efclif@efclif.com for review at least 15 working days prior to submission.

In all communications with EF CLIF, authors should reference the title of the previously registered project that was granted access to data and/or samples from EF CLIF-promoted and/or -funded studies.

The EF CLIF Governing Board shall be the governing body responsible for all matters relating to publication of findings using samples and/or data from EF CLIF -promoted and/or -funded studies. If the EF CLIF Governing Board determines that the submitted publication is not compliant with this policy or any other EF CLIF policies or agreements in force at the time of internal publication review or anytime thereafter, EF CLIF will inform the leading and corresponding author(s) and request the necessary changes or updates.

Definitions

Parent study: main study having one or more ancillary studies.

Ancillary study: an independent research project that uses data and/or samples from a parent study to extend knowledge in scientific areas beyond the original scope of the parent study. An ancillary study may require additional data or sample collection (i.e., auxiliary study) and should not interfere with the primary objectives of the parent study.

Document history

Version	Author / Job title	Date approved	Summary of main changes and reasons
01	Lidia Garcia-Campmany <i>Scientific Communications Manager</i>	13 November 2023	Created
02	Lidia Garcia-Campmany <i>Scientific Communications Manager</i>	25 September 2024	Acknowledgements statement updated to reflect current funding sources Procedure for the review of publications and abstracts updated according to current internal procedures

<p>This document has been reviewed by:</p> <p>Anna Bosch, General Manager at EF CLIF</p>	<p>This document has been approved by:</p> <p>Anna Bosch, General Manager at EF CLIF for and on behalf of the Board of Trustees</p>
---	--